News - Licensing, Diabetes


Current filters:


Popular Filters

1 to 25 of 54 results

Ligand licenses five programs to Viking Therapeutics


US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech


Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Celladon signs option agreement with Servier


USA-based biotech firm Celladon has entered into an option agreement with French independent drugmaker…


Merck and Samsung Bioepis expand collaboration to insulin glargine candidate

Merck and Samsung Bioepis expand collaboration to insulin glargine candidate


US pharma giant Merck & Co and South Korea’s Samsung Bioepis have expanded their collaboration with…

BiosimilarsDiabetesInsulin Glargine [rDNA origin] InjectionLantusLicensingMerck & CoPharmaceuticalResearchSamsung BioepisSanofi

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments


Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

Chinese, European drugmakers strike $500 million-plus deal


An agreement worth more than $500 million between privately-held Swiss/Greek pharmaceutical and clinical…

DiabetesEuropeFochon PharmaFosun PharmaLicensingPharmaceuticalResearchSellas Life Sciences

PDL BioPharma secures royalties on diabetes products in $240m deal

PDL BioPharma secures royalties on diabetes products in $240m deal


PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2…

DepomedDiabetesFinancialGlumetzaInvokanaJanumetLicensingmetforminNorth AmericaPDL BioPharmaPharmaceutical

Evolva to license EV-077 to Serodus


Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term…

BiotechnologyDiabetesEV-077EvolvaLicensingNephrology and HepatologyPharmaceuticalSerodus

Depomed expands geographic scope of metformin deal with Merck


USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

ThromboGenics gains rights to DME drug


Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Merck & Co to co-promote diabetes agent ipragliflozin in Japan


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

Sirona Biochem signs LoI with leading Chinese diabetes company


Canada's Sirona Biotech (TSX VENTURE:SBM) has signed a letter of intent to provide an exclusive license…

Asia-PacificBiotechnologyDiabetesFosun PharmaLicensingPharmaceuticalSGLT2Sirona BiochemWanbang Pharma

Adocia re-acquires exclusive rights to insulin analog from US drug major


French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY)…

AdociaBiotechnologyDiabetesEli LillyLicensingPharmaceutical

Eli Lilly exercises rights to diabetes drug candidate TT-401 from Transition Therapeutics


Canada's Transition Therapeutics (TSX: TTH) announced this morning (June 17) that US drug major Eli Lilly…

DiabetesEli LillyLicensingPharmaceuticalTransition TherapeuticsTT-401

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research


Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx


US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Abide Therapeutics in up to $430 million deal with Merck & Co for type 2 diabetes and metabolic disease


Privately-held biopharma firm Abide Therapeutics has entered into a collaboration agreement with US…

Abide TherapeuticsDiabetesLicensingMerck & CoMetabolicsPharmaceuticalResearch

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug


US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Emisphere earns $10 million on amended deal with Novo Nordisk


USA-based Emisphere Technologies (OTCBB: EMIS) says that it has agreed with Danish insulin giant Novo…

DiabetesEmisphereLicensingNovo NordiskPharmaceuticalResearch

Merck KGaA links with Bristol-Myers for Glucophage promotion in China


German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

1 to 25 of 54 results

Back to top